Bigora Sian

CDO bought 1,986 shares at $2.69; 36.0% increase to 7.5K-share position. Stock down -78.7% from high, company unprofitable.

Chief Development Officer Sian purchased 1,986 shares of Processa Pharmaceuticals at $2.69 on 2026-04-30, increasing holdings by 36.0% to 7.5K shares total—a material position increase. The timing coincides with a cluster of 5 other insiders buying within the past 14 days, suggesting coordinated activity during a period of depressed valuation; the stock trades at -78.7% from its 52-week high of $11.97 and currently sits at $2.55, down 15.0% over 90 days. However, the company's fundamentals remain deeply challenged: revenue is $0.00 (latest quarter), net income is $-3.4M, and the market cap is only $7.0M—reflecting a pre-revenue biotech with significant cash burn. Sian's cross-ticker track record shows 2 prior buys averaging +6.5% 30-day returns, but at this specific ticker, timing outcomes remain inconclusive: his prior PCSA buy on 2026-03-31 shows +6.5% 30-day return but 90-day outcome is not yet measurable. The cluster pattern and substantial position increase warrant attention to whether cash reserves and runway support continued operations.

CDO Bigora Sian buys 1,799 shares of PCSA at $2.97 (total $5.3K); stock -74.1% from 52-week high, unprofitable fundamentals.

Bigora Sian, Chief Development Officer, purchased 1,799 shares at $2.97 on 2026-04-15, expanding his position by 48.5% to 5,510 shares post-transaction. This buy occurs within a cluster of 5 other insider purchases at the same company within the past 14 days, suggesting coordinated interest at current valuations. The stock trades at $3.10 currently, -74.1% from its 52-week high of $11.97, and the company reported $0.00 revenue in the latest quarter with net income of -$3.4M and an unprofitable full-year result. The purchase at a depressed price-level amid sector-wide weakness requires further scrutiny into whether the cluster buying reflects material non-public information or simply coincidental interest in an undervalued, cash-constrained biotech.

CDO Bigora Sian buys 2,107 shares at $2.54; 8 other insiders bought in past 14 days as company trades -78.3% from 52-week high with $-3.4M annual loss.

Bigora Sian, Chief Development Officer of Processa Pharmaceuticals, purchased 2,107 shares at $2.54 on 2026-03-31, increasing his holdings by +131.4% from 1,604 to 3,711 shares. This transaction is part of a cluster pattern: 8 other insiders also bought within the past 14 days, suggesting coordinated or coincident confidence at current levels. The purchase occurs while the stock is trading at $2.60, which is -78.3% from its 52-week high of $11.97, and amid fundamental headwinds—the company posted zero quarterly revenue and negative annual net income of $-3,436,573.00, with a market cap of $6,916,101.40. The coincidence of multiple insider accumulation in a deeply out-of-favor, unprofitable microcap suggests either: (1) insiders perceive fundamental value at depressed prices, or (2) the purchases reflect routine rebalancing or other non-conviction motives; absent additional context on timing flags or transaction nature, the cluster pattern and magnitude of Sian's holdings increase warrant investor scrutiny of the underlying business trajectory.